Indapta Therapeutics is a privately held biotechnology company focused on developing a natural killer (NK) cell therapy platform aimed at treating both blood and solid tumor cancers. The company specializes in a proprietary off-the-shelf, non-engineered, and allogeneic G-NK cell designed to enhance the immune response and significantly improve the effectiveness of antibody therapies. Through its innovative approach, Indapta Therapeutics seeks to provide healthcare providers with advanced treatment options for patients suffering from cancer, leveraging the potent antibody-dependent cellular cytotoxicity (ADCC) activity of its NK cell therapy.
Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for various diseases, particularly those affecting muscle and the central nervous system (CNS). Founded in 2019 and based in Waltham, Massachusetts, the company specializes in creating rationally designed adeno-associated virus (AAV) vectors. By integrating synthetic and systems biology with high-throughput screening and advanced resolution techniques, Affinia Therapeutics aims to address significant unmet medical needs. The company’s innovative approach allows for the development of novel gene therapies with enhanced properties, targeting the treatment of devastating diseases and improving the lives of affected individuals.
Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for various diseases, particularly those affecting muscle and the central nervous system (CNS). Founded in 2019 and based in Waltham, Massachusetts, the company specializes in creating rationally designed adeno-associated virus (AAV) vectors. By integrating synthetic and systems biology with high-throughput screening and advanced resolution techniques, Affinia Therapeutics aims to address significant unmet medical needs. The company’s innovative approach allows for the development of novel gene therapies with enhanced properties, targeting the treatment of devastating diseases and improving the lives of affected individuals.
Micro-Macinazione S.A. operates as an engineering company for the development of jet-mill technologies. Its services include micronization services using equipment adapted to the properties of the product to improve the performance of each unit; highly potent compounds to protect personnel, products, and environment; research and development services in pharmaceutical powders technologies and competencies in process development; and engineering solutions, including design and manufacturing of jet mills (both spiral and opposed), glove boxes, and pneumatic conveyors. The company provides its services to pharmaceutical industry and fine chemical industry. The company was founded in 1970 and is based in Molinazzo di Monteggio, Switzerland. As of July 26, 2017, Micro-Macinazione S.A. operates as a subsidiary of Lonza Group Ltd.
PharmaCell B.V. is a contract manufacturing organization specializing in cellular therapies and regenerative medicine, based in Maastricht, the Netherlands. Founded in 2005, the company operates GMP-certified manufacturing facilities in Maastricht and Geleen, supporting Phase I to Phase III clinical trials and producing commercial cell therapy products for the European market. PharmaCell offers a range of services including operational expertise, technology transfer, process development, and logistics, facilitating the transition of research and development products into clinical applications. The company serves leading clients in the cell therapy sector, leveraging its extensive network to enhance collaboration and support for innovative healthcare solutions. As of 2017, PharmaCell operates as a subsidiary of Lonza Group Ltd.
Exosomics focuses on creating innovative tests for cancer screening and liquid biopsy through the analysis of circulating extracellular vesicles. The company specializes in biotechnology equipment that enhances the pre-analytical processes necessary to isolate tumor-derived extracellular vesicles and exosomes from human biofluids. By extracting genomic DNA and RNA from these components, Exosomics aims to provide reliable and cost-effective diagnostic solutions. This approach facilitates improved treatment options for cancer patients by enabling more accurate detection and monitoring of the disease.
HansaBioMed Life Sciences Ltd is a Company entirely dedicated to research and development of products in the field of Exosome Sciences. HansaBioMed mission is to develop and commercialize proprietary platforms, kits, reagents and equipment for exosomes research in the Life Science market.
Capsugel is a prominent developer and manufacturer of innovative dosage forms and solutions, headquartered in Morristown, New Jersey. The company specializes in producing a variety of capsules, including inhalation, gelatin, clinical, and polymer capsules. By leveraging its expertise in science and engineering, Capsugel assists healthcare companies in enhancing the bioavailability, targeted delivery, and overall performance of their biopharmaceutical, consumer health, and nutrition products. As a leading provider of empty, two-piece hard capsules, Capsugel has established a strong reputation for quality, reliability, and innovation in the pharmaceutical industry.
ConnectedYard Inc., based in Campbell, California, specializes in smart technology for outdoor living, starting with pool and hot tub care through its product, pHin. This innovative solution combines a Bluetooth and Wi-Fi-enabled water monitor with a mobile app that simplifies water management. The app alerts users when water chemistry requires adjustment, providing clear dosing instructions for necessary chemicals. Additionally, it offers convenient access to a network of qualified pool service technicians, facilitating on-demand assistance. As ConnectedYard continues to develop its offerings, it aims to expand its smart solutions to cover various aspects of outdoor living, including irrigation and lighting, enhancing the overall experience of backyard management.
InterHealth Nutraceuticals is a developer and manufacturer of proprietary branded nutraceutical ingredients, focusing on the research, marketing, and distribution of these products globally. The company supplies its high-quality ingredients to manufacturers of dietary supplements, functional foods, beverages, and cosmetic products. Among its notable ingredient brands are Super CitriMax, UC-II, ChromeMate, and L-OptiZinc. With a strong commitment to thorough research and outstanding customer service, InterHealth has built a reputation for quality and innovation in the nutraceutical industry since its inception in 1987. The company continues to seek new value-added ingredients and collaborates with clients to create proprietary blends tailored to specific health supplement needs.
TRL is a fast-growing hepatocyte provider with products supporting in vitro evaluation of metabolism, drug-drug interactions, drug transporter activity, toxicity of drug candidates and other applications. Triangle Research Labs has facilities based in Research Triangle Park, North Carolina (USA). Triangle Research Labs was established in 2012 and has quickly gained a reputation for high-quality products and a unique ability to understand each customer’s specific needs. This combination makes TRL a great asset to Lonza’s mission of serving customers in the bioresearch space through a culture of trust and care.
Zelam Limited is a New Zealand-based company that specializes in the research, development, production, and marketing of crop protection products for both local and international markets. Founded in 1988 and headquartered in New Plymouth, Zelam offers a range of products including fungicides, herbicides, insecticides, foliar nutrients, and additives. The company also engages in the manufacturing and treatment of engineered wood products. Zelam conducts testing in its micro laboratory and performs trials in regions such as New Zealand, Australia, and Hawaii. Its products are marketed under various brand names, including TAG G2, Vixen, Taratek, and Permatek. Originally established as Taranaki Nuchem Ltd., the company rebranded to Zelam Limited in April 2006 and operates as a subsidiary of Lonza Group Ltd.
Odyssey Thera, Inc. is a biopharmaceutical company focused on developing therapies for cancer treatment. Founded in 2002 and based in San Ramon, California, the company employs a cellular pharmacology strategy to identify and develop medicines targeting human diseases. Odyssey Thera specializes in deciphering biologically-relevant pathways in living human cells, which enhances drug discovery and improves methods for assessing environmental chemical toxicity. Its product pipeline features small molecule inhibitors designed to block key signaling nodes in cancer cells, reflecting the company's commitment to advancing innovative cancer therapies.
Moda Technology Partners is a commercial software company dedicated to enhancing automation and regulatory compliance in pharmaceutical manufacturing. The company specializes in a mobile data acquisition platform that enables organizations to automate quality control processes for pharmaceuticals and consumer products. By leveraging mobile computing technology, Moda's software systems assist pharmaceutical clients in increasing operational efficiency, improving product quality, and reducing manufacturing costs.
AlgoNomics is a Belgium-based biotech company specializing in structural bioinformatics services aimed at developing rationally designed therapeutics, particularly in the field of immunotherapy. The company possesses a proprietary platform that includes advanced tools for analyzing protein-protein and protein-peptide interactions. Its flagship product, the Epibase platform, focuses on T-cell epitope identification across diverse population groups, facilitating the discovery of vaccines and therapeutic proteins. By providing comprehensive immunogenicity screening services, AlgoNomics supports the development of biotherapeutics designed to enhance immune responses.
Cilian is an emerging biotechnology company developing and marketing a novel expression system. The Company uses a species of Ciliates, a eukaryotic single-cell organism, for the production of enzymes and therapeutic proteins. While Ciliates secrete a number of therapeutically relevant enzymes with high expression rates by nature, recombinant proteins are produced by Ciliates using genetically modified cells. Leveraging the unique capabilities of the Ciliates, the Company aims to produce proteins at an unmatched quality and price, thereby fulfilling its mission to improve human health by facilitating access to biopharmaceuticals.
Amaxa Biosystems GmbH specializes in developing and commercializing gene transfer technologies, notably through its Nucleofector Technology, which facilitates the non-viral transfer of various substrates, including DNA, RNA, and peptides into cells. The company provides a range of products and services, including transfection reagents, antibiotics for combating microbial contamination, and expression vectors for producing fluorescent proteins in mammalian cells. Amaxa's solutions are utilized in primary cell research and are available in multiple countries, including Canada, China, and Japan. Founded in 1998 and headquartered in Cologne, Germany, Amaxa has been a subsidiary of Lonza Group AG since 2008.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.